Skip to main content
. Author manuscript; available in PMC: 2022 Nov 2.
Published in final edited form as: Adv Cancer Res. 2021 Aug 13;153:237–266. doi: 10.1016/bs.acr.2021.07.006

Fig. 3.

Fig. 3

RAS-targeting peptide-PROTACs. Anti-RAS biologics are genetically fused to an E3 ubiquitin ligase resulting in recruitment of the complex to RAS, polyubiquitination and subsequent proteasomal degradation. The peptide-PROTAC, however, can be recycled to initiate multiple rounds of RAS degradation.